4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Aplastic Anemia by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 161 ongoing clinical trials involving Aplastic Anemia
Of the 161 trials,86 trials are in Phase II
Furthermore, 25 trials are in Phase I/II

Number of ongoing Clinical Trials (for drugs) involving Aplastic Anemia by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Aplastic Anemia, a Hematological disorder. The highest number of ongoing clinical trials involving Aplastic Anemia is in Asia-Pacific. North America and Europe are among some of the other prominent regions involved in Aplastic Anemia-related drug trials.

National Heart Lung and Blood Institute: The leading ongoing Aplastic Anemia-related clinical trials sponsor

National Heart Lung and Blood Institute, the United States of America-based government institute, is the top sponsor for Aplastic Anemia-related ongoing clinical trials.

Institute of Hematology & Blood Diseases Hospital, Jiangsu Hengrui Medicine Co Ltd, University of Texas MD Anderson Cancer Center, Novartis AG, and Shanghai Jiao Tong University School of Medicine are a few other notable sponsors involving Aplastic Anemia.

A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Aplastic Anemia

Eltrombopag olamine (Revolade/ Promacta/ Revoleyd/ Rebozet), Romiplostim (Nplate), and Methylprednisolone (Solu-Medrol, Depo-Medrol, Medrol, Medrate, Depo-Medrate, Medrol Acetate, Solu-Medrone, Solu-Moderin, Depo-Medrone, Methylprednisolone Sodium Succinate, Promedrol, Medrol A, Medroxyprogesterone Acetate Greenstone) are among the key marketed drugs involving Aplastic Anemia.

Eltrombopag olamine (Revolade/ Promacta/ Revoleyd/ Rebozet) is a small-molecule, nonpeptide thrombopoietin receptor agonist. It functions via the Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) Agonist. It is formulated as film coated tablets and powder for suspension for oral route of administration. Promacta is indicated for the treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy, for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenia (ITP) who has had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Eltrombopag olamine was first approved in 2008 and is marketed globally including the US, the UK, France, Germany, China, and Japan by several prominent pharma giants including Novartis AG.

Romiplostim (Nplate), is an Fc-peptide fusion protein. It functions via Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) Agonist mechanism of action. It is formulated as lyophilized powder for solution for subcutaneous route of administration. Nplate is indicated for treatment of adults, and pediatrics 1 year and older with long-term immune thrombocytopenic purpura (ITP), and for the treatment of aplastic anemia (AA) in patients who have had an inadequate response to conventional therapy in adults and also indicated to increase survival in adults and in pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation. Romiplostim was first approved in 2008 and is marketed globally including the US, the UK, France, Germany, and Japan by several prominent pharma giants including Amgen Inc.